Key result
SGLT2 inhibitors show potential as disease-modifying therapy in RHD via anti-inflammatory and antifibrotic effects.
Why the study?
Do SGLT2 inhibitors attenuate valvular inflammation and fibrosis to modify disease progression and improve clinical outcomes in patients with rheumatic heart disease?
Do SGLT2 inhibitors attenuate valvular inflammation and fibrosis to modify disease progression and improve clinical outcomes in patients with rheumatic heart disease?
Answers are grounded in this paper and cite their sources.
This review highlights the mechanistic rationale and early clinical evidence supporting SGLT2 inhibitors as a potential low-cost, first-in-class disease-modifying pharmacotherapy for rheumatic heart disease, calling for dedicated clinical outcomes trials.
Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and premature mortality among children and young adults, particularly in low- and middle-income countries. Current management relies on antibiotic prophylaxis and late-stage valve interventions, with no approved pharmacologic therapies targeting the immune-inflammatory and fibrotic processes driving disease progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally developed for glycemic control, have demonstrated cardiovascular and renal benefits beyond metabolic effects. Their pleiotropic properties - including anti-inflammatory, antifibrotic, antithrombotic, and endothelial-protective actions - align with key mechanisms underlying RHD progression. Preclinical and translational evidence suggests that SGLT2 inhibition can attenuate valvular inflammation, limit fibrosis, and reduce maladaptive remodeling. Emerging clinical data from other valvular diseases indicate potential improvements in hemodynamics and outcomes. This review highlights SGLT2 inhibitors as promising disease-modifying therapies for RHD and underscores the need for dedicated clinical trials to confirm their therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Morel et al. (2026) conducted a review in Rheumatic heart disease (RHD) and valvular heart disease. Sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin, empagliflozin) was evaluated. SGLT2 inhibitors exhibit anti-inflammatory, antifibrotic, and endothelial-protective effects in preclinical and early clinical studies, supporting their potential as disease-modifying therapy in RHD.
Synapse has enriched 10 related papers. Consider them for comparative context: